30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Spyre Therapeutics Inc (SYRE)

Track

Over the last 90 days, Spyre Therapeutics Inc. has seen significant insider selling activity, totaling over $837 million. Notably, Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. executed large sales. This activity occurred despite a substantial 90-day stock price increase of over 104%. The last earnings report showed a miss.
Stock chart
Ticker: SYRE Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
SCOTT BURROWS
Officer
1 sale — total 100,000 USD
Proposed sale 25 Jun 2026
Value US$321,139.11 | Price 466.05 | Shares 45,959
Proposed sale 23 Jun 2026
Value US$3,692,322.38 | Price 405.25 | Shares 79,046
Sale 23 Jun 2026
Value US$100,000.00 | Price 85.31 | Shares 1,000
Planned sale 22 Jun 2026
Value US$100,000.00 | Price 100.00 | Shares 1,000
Proposed sale 22 Jun 2026
Value US$100,000.00 | Price 88.34 | Shares 1,000
Proposed sale 22 Jun 2026
Value US$100,000.00 | Price 88.34 | Shares 1,000
Planned sale 3 Jun 2026
Value US$624,975.00 | Price 75.00 | Shares 8,333
Proposed sale 3 Jun 2026
Value US$1,152,689.72 | Price 69.16 | Shares 16,667
Planned sale 1 Jun 2026
Value US$235,125.72 | Price 71.38 | Shares 3,294
Planned sale 1 Jun 2026
Value US$574,504.50 | Price 70.50 | Shares 8,149
Planned sale 1 Jun 2026
Value US$246,855.80 | Price 69.40 | Shares 3,557
Planned sale 1 Jun 2026
Value US$223,386.00 | Price 72.06 | Shares 3,100
Planned sale 1 Jun 2026
Value US$183,931.23 | Price 70.77 | Shares 2,599
Planned sale 1 Jun 2026
Value US$125,619.75 | Price 69.75 | Shares 1,801
Planned sale 8 May 2026
Value US$1,451,919.15 | Price 75.35 | Shares 19,269
Planned sale 8 May 2026
Value US$1,855,094.64 | Price 74.76 | Shares 24,814
Planned sale 8 May 2026
Value US$2,470,578.36 | Price 73.72 | Shares 33,513
Planned sale 8 May 2026
Value US$174,458.28 | Price 72.57 | Shares 2,404
Proposed sale 8 May 2026
Value US$5,848,000.00 | Price 73.10 | Shares 80,000
Planned sale 1 May 2026
Value US$30,148.00 | Price 75.37 | Shares 400
Planned sale 1 May 2026
Value US$377,401.40 | Price 74.60 | Shares 5,059
Planned sale 1 May 2026
Value US$763,798.92 | Price 73.74 | Shares 10,358
Planned sale 1 May 2026
Value US$931,954.38 | Price 72.94 | Shares 12,777
Planned sale 1 May 2026
Value US$628,082.12 | Price 71.56 | Shares 8,777
Planned sale 1 May 2026
Value US$1,387,910.16 | Price 70.61 | Shares 19,656
Planned sale 1 May 2026
Value US$1,481,406.18 | Price 69.53 | Shares 21,306
Planned sale 1 May 2026
Value US$892,125.00 | Price 71.37 | Shares 12,500
Planned sale 1 May 2026
Value US$22,488.00 | Price 74.96 | Shares 300
Planned sale 1 May 2026
Value US$126,191.00 | Price 74.23 | Shares 1,700
Planned sale 1 May 2026
Value US$226,734.00 | Price 73.14 | Shares 3,100
Planned sale 1 May 2026
Value US$71,760.00 | Price 71.76 | Shares 1,000
Planned sale 1 May 2026
Value US$254,772.00 | Price 70.77 | Shares 3,600
Planned sale 1 May 2026
Value US$368,562.00 | Price 69.54 | Shares 5,300
Proposed sale 1 May 2026
Value US$2,047,375.00 | Price 74.45 | Shares 27,500
Proposed sale 1 May 2026
Value US$5,831,891.85 | Price 74.45 | Shares 78,333
Planned sale 1 Apr 2026
Value US$132,587.52 | Price 49.92 | Shares 2,656
Planned sale 1 Apr 2026
Value US$607,324.80 | Price 49.20 | Shares 12,344
Planned sale 1 Apr 2026
Value US$397,900.00 | Price 50.00 | Shares 7,958
Planned sale 1 Apr 2026
Value US$64,974.00 | Price 49.98 | Shares 1,300
Planned sale 1 Apr 2026
Value US$305,102.00 | Price 49.21 | Shares 6,200
Proposed sale 1 Apr 2026
Value US$401,401.52 | Price 50.44 | Shares 7,958
Planned sale 3 Mar 2026
Value US$8,332.00 | Price 41.66 | Shares 200
Planned sale 3 Mar 2026
Value US$93,288.00 | Price 40.56 | Shares 2,300
Proposed sale 3 Mar 2026
Value US$424,900.00 | Price 42.49 | Shares 10,000
Planned sale 2 Mar 2026
Value US$386,659.00 | Price 42.49 | Shares 9,100
Planned sale 2 Mar 2026
Value US$246,207.00 | Price 41.73 | Shares 5,900
Proposed sale 2 Mar 2026
Value US$2,580,600.00 | Price 43.01 | Shares 60,000
Planned sale 2 Feb 2026
Value US$461,593.41 | Price 32.87 | Shares 14,043
Planned sale 2 Feb 2026
Value US$461,593.41 | Price 32.87 | Shares 14,043
Planned sale 2 Feb 2026
Value US$30,451.74 | Price 31.82 | Shares 957
Planned sale 2 Jan 2026
Value US$3,239.00 | Price 32.39 | Shares 100
Planned sale 2 Jan 2026
Value US$69,651.89 | Price 31.79 | Shares 2,191
Planned sale 2 Jan 2026
Value US$387,243.23 | Price 30.47 | Shares 12,709
Planned sale 1 Dec 2025
Value US$119,469.15 | Price 29.83 | Shares 4,005
Planned sale 1 Dec 2025
Value US$315,886.35 | Price 28.73 | Shares 10,995
Planned sale 3 Nov 2025
Value US$398,552.70 | Price 23.66 | Shares 16,845
Planned sale 3 Nov 2025
Value US$651,225.15 | Price 23.13 | Shares 28,155
Proposed sale 3 Nov 2025
Value US$2,201,400.00 | Price 24.46 | Shares 90,000
Sale 2 Sep 2025
Value US$299,639.28 | Price 16.26 | Shares 18,428
Planned sale 6 Nov 2024
Value US$246,312.77 | Price 36.76 | Shares 6,700
Planned sale 25 Oct 2024
Value US$10,929.00 | Price 36.43 | Shares 300
Proposed sale 25 Oct 2024
Value US$235,900.00 | Price 33.70 | Shares 7,000
Sale 3 Sep 2024
Value US$522,073.86 | Price 28.17 | Shares 18,531
Buy 25 Aug 2022
Value US$50,472.00 | Price 0.56 | Shares 90,000
Planned buy 8 Jun 2022
Value US$20,022.00 | Price 0.71 | Shares 28,200
Buy 16 Mar 2022
Value US$187,705.18 | Price 2.34 | Shares 80,079
Buy 15 Mar 2022
Value US$78,942.28 | Price 1.86 | Shares 42,417
Buy 14 Mar 2022
Value US$130,220.96 | Price 1.93 | Shares 67,472
Buy 11 Mar 2022
Value US$71,779.73 | Price 2.06 | Shares 34,777
Buy 11 Mar 2022
Value US$156,000.00 | Price 2.08 | Shares 75,000
Buy 13 Dec 2021
Value US$53,600.25 | Price 3.65 | Shares 14,685
Planned buy 10 Dec 2021
Value US$39,472.50 | Price 3.75 | Shares 10,526
Buy 10 Dec 2021
Value US$49,333.40 | Price 3.65 | Shares 13,516
Planned buy 9 Dec 2021
Value US$159,499.60 | Price 3.70 | Shares 43,108
Buy 9 Dec 2021
Value US$446,758.73 | Price 3.67 | Shares 121,799
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-25 2026-06-25 PrS Proposed sale
2.0
SCOTT BURROWS

Officer

Officer
45,959
466.05
US$321,139 		45,959 466.05 US$321,139
2026-06-23 2026-06-23 PrS Proposed sale
3.5
Fairmount Healthcare Fund II L.P.

Director

Non-Executive Director
79,046
405.25
US$3,692,322 		79,046 405.25 US$3,692,322
2026-06-23 2026-06-23 S Sale
3.5
Fairmount Funds Management LLC
Non-Executive Director
68,883 -34.5%
56.18
US$2,496,592 		68,883 -34.5% 56.18 US$2,496,592
2026-06-23 2026-06-22 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
1,000 -22.6%
100.00
US$100,000 		1,000 -22.6% 100.00 US$100,000
2026-06-22 2026-06-22 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
1,000
88.34
US$100,000 		1,000 88.34 US$100,000
2026-06-22 2026-06-22 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
1,000
88.34
US$100,000 		1,000 88.34 US$100,000
2026-06-03 2026-06-03 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
8,333 -100.0%
75.00
US$624,975 		8,333 -100.0% 75.00 US$624,975
2026-06-03 2026-06-03 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
16,667
69.16
US$1,152,690 		16,667 69.16 US$1,152,690
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,294 -0.5%
71.38
US$235,126 		3,294 -0.5% 71.38 US$235,126
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
8,149 -1.3%
70.50
US$574,504 		8,149 -1.3% 70.50 US$574,504
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,557 -0.6%
69.40
US$246,856 		3,557 -0.6% 69.40 US$246,856
2026-06-03 2026-06-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
3,100 -3.1%
72.06
US$223,386 		3,100 -3.1% 72.06 US$223,386
2026-06-03 2026-06-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
2,599 -2.5%
70.77
US$183,931 		2,599 -2.5% 70.77 US$183,931
2026-06-03 2026-06-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
1,801 -1.7%
69.75
US$125,620 		1,801 -1.7% 69.75 US$125,620
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
19,269 -17.9%
75.35
US$1,451,919 		19,269 -17.9% 75.35 US$1,451,919
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
24,814 -18.7%
74.76
US$1,855,095 		24,814 -18.7% 74.76 US$1,855,095
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
33,513 -20.2%
73.72
US$2,470,578 		33,513 -20.2% 73.72 US$2,470,578
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
2,404 -1.4%
72.57
US$174,458 		2,404 -1.4% 72.57 US$174,458
2026-05-08 2026-05-08 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
80,000
73.10
US$5,848,000 		80,000 73.10 US$5,848,000
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
400 -100.0%
75.37
US$30,148 		400 -100.0% 75.37 US$30,148
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
5,059 -92.7%
74.60
US$377,401 		5,059 -92.7% 74.60 US$377,401
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
10,358 -65.5%
73.74
US$763,799 		10,358 -65.5% 73.74 US$763,799
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
12,777 -44.7%
72.94
US$931,954 		12,777 -44.7% 72.94 US$931,954
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
8,777 -23.5%
71.56
US$628,082 		8,777 -23.5% 71.56 US$628,082
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
19,656 -34.5%
70.61
US$1,387,910 		19,656 -34.5% 70.61 US$1,387,910
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
21,306 -27.2%
69.53
US$1,481,406 		21,306 -27.2% 69.53 US$1,481,406
2026-05-01 2026-05-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
12,500 -11.3%
71.37
US$892,125 		12,500 -11.3% 71.37 US$892,125
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
300 -0.0%
74.96
US$22,488 		300 -0.0% 74.96 US$22,488
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,700 -0.3%
74.23
US$126,191 		1,700 -0.3% 74.23 US$126,191
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,100 -0.5%
73.14
US$226,734 		3,100 -0.5% 73.14 US$226,734
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -0.2%
71.76
US$71,760 		1,000 -0.2% 71.76 US$71,760
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,600 -0.6%
70.77
US$254,772 		3,600 -0.6% 70.77 US$254,772
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
5,300 -0.8%
69.54
US$368,562 		5,300 -0.8% 69.54 US$368,562
2026-05-01 2026-05-01 PrS Proposed sale
2.0
SCOTT BURROWS

Officer

Officer
27,500
74.45
US$2,047,375 		27,500 74.45 US$2,047,375
2026-05-01 2026-05-01 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
78,333
74.45
US$5,831,892 		78,333 74.45 US$5,831,892
2026-04-03 2026-04-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
2,656 -0.4%
49.92
US$132,588 		2,656 -0.4% 49.92 US$132,588
2026-04-03 2026-04-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
12,344 -1.9%
49.20
US$607,325 		12,344 -1.9% 49.20 US$607,325
2026-04-03 2026-04-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
7,958 -100.0%
50.00
US$397,900 		7,958 -100.0% 50.00 US$397,900
2026-04-03 2026-04-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
1,300 -1.3%
49.98
US$64,974 		1,300 -1.3% 49.98 US$64,974
2026-04-03 2026-04-01 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
6,200 -5.9%
49.21
US$305,102 		6,200 -5.9% 49.21 US$305,102
2026-04-01 2026-04-01 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
7,958
50.44
US$401,402 		7,958 50.44 US$401,402
2026-03-03 2026-03-03 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
200 -0.2%
41.66
US$8,332 		200 -0.2% 41.66 US$8,332
2026-03-03 2026-03-03 PlS Planned sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
2,300 -2.3%
40.56
US$93,288 		2,300 -2.3% 40.56 US$93,288
2026-03-03 2026-03-03 PrS Proposed sale
2.0
SCOTT BURROWS

Officer

Officer
10,000
42.49
US$424,900 		10,000 42.49 US$424,900
2026-03-03 2026-03-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
9,100 -1.4%
42.49
US$386,659 		9,100 -1.4% 42.49 US$386,659
2026-03-03 2026-03-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
5,900 -0.9%
41.73
US$246,207 		5,900 -0.9% 41.73 US$246,207
2026-03-02 2026-03-02 PrS Proposed sale
1.5
CAMERON TURTLE

Director; Officer

Executive Director
60,000
43.01
US$2,580,600 		60,000 43.01 US$2,580,600
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
14,043 -2.1%
32.87
US$461,593 		14,043 -2.1% 32.87 US$461,593
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
14,043 -2.1%
32.87
US$461,593 		14,043 -2.1% 32.87 US$461,593
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
957 -0.1%
31.82
US$30,452 		957 -0.1% 31.82 US$30,452
2026-01-06 2026-01-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
100 -0.0%
32.39
US$3,239 		100 -0.0% 32.39 US$3,239
2026-01-06 2026-01-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
2,191 -0.3%
31.79
US$69,652 		2,191 -0.3% 31.79 US$69,652
2026-01-06 2026-01-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
12,709 -1.9%
30.47
US$387,243 		12,709 -1.9% 30.47 US$387,243
2025-12-03 2025-12-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
4,005 -0.6%
29.83
US$119,469 		4,005 -0.6% 29.83 US$119,469
2025-12-03 2025-12-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
10,995 -1.6%
28.73
US$315,886 		10,995 -1.6% 28.73 US$315,886
2025-11-05 2025-11-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
16,845 -2.3%
23.66
US$398,553 		16,845 -2.3% 23.66 US$398,553
2025-11-05 2025-11-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
28,155 -3.8%
23.13
US$651,225 		28,155 -3.8% 23.13 US$651,225
2025-11-03 2025-11-03 PrS Proposed sale
1.5
CAMERON TURTLE

Director; Officer

Executive Director
90,000
24.46
US$2,201,400 		90,000 24.46 US$2,201,400
2025-09-03 2025-09-02 S Sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
18,428 -15.8%
16.26
US$299,639 		18,428 -15.8% 16.26 US$299,639
2024-11-08 2024-11-06 PlS Planned sale
2.3
Albers Jeffrey W.
Non-Executive Director
6,700 -19.7%
36.76
US$246,313 		6,700 -19.7% 36.76 US$246,313
2024-10-28 2024-10-25 PlS Planned sale
2.3
Albers Jeffrey W.
Non-Executive Director
300 -0.9%
36.43
US$10,929 		300 -0.9% 36.43 US$10,929
2024-10-25 2024-10-25 PrS Proposed sale
2.3
SESSIONS, LLC

Director

Non-Executive Director
7,000
33.70
US$235,900 		7,000 33.70 US$235,900
2024-09-05 2024-09-03 S Sale
2.0
Burrows Scott L

Chief Financial Officer

Officer
18,531 -13.7%
28.17
US$522,074 		18,531 -13.7% 28.17 US$522,074
2022-08-25 2022-08-25 B Purchase
4.2
Souza Marcio
Non-Executive Director
90,000 +inf%
0.56
US$50,472 		90,000 +inf% 0.56 US$50,472
2022-06-10 2022-06-08 PP Planned purchase
Hanley Jr. Michael Conick

Chief Commercial Officer

Officer
28,200 +352.5%
0.71
US$20,022 		28,200 +352.5% 0.71 US$20,022
2022-03-18 2022-03-16 B Purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
80,079 +17.0%
2.34
US$187,705 		80,079 +17.0% 2.34 US$187,705
2022-03-15 2022-03-15 B Purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
42,417 +9.8%
1.86
US$78,942 		42,417 +9.8% 1.86 US$78,942
2022-03-15 2022-03-14 B Purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
67,472 +18.6%
1.93
US$130,221 		67,472 +18.6% 1.93 US$130,221
2022-03-15 2022-03-11 B Purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
34,777 +10.6%
2.06
US$71,780 		34,777 +10.6% 2.06 US$71,780
2022-03-15 2022-03-11 B Purchase
1.8
Alspaugh Jonathan

Chief Financial Officer

Officer
75,000 +83.0%
2.08
US$156,000 		75,000 +83.0% 2.08 US$156,000
2021-12-13 2021-12-13 B Purchase
1.8
Shanafelt Armen
Non-Executive Director
14,685 +10.9%
3.65
US$53,600 		14,685 +10.9% 3.65 US$53,600
2021-12-13 2021-12-10 PP Planned purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
10,526 +3.3%
3.75
US$39,472 		10,526 +3.3% 3.75 US$39,472
2021-12-13 2021-12-10 B Purchase
1.8
Shanafelt Armen
Non-Executive Director
13,516 +11.1%
3.65
US$49,333 		13,516 +11.1% 3.65 US$49,333
2021-12-13 2021-12-09 PP Planned purchase
2.6
Quinn Anthony G.

President & CEO

Executive Director
43,108 +15.7%
3.70
US$159,500 		43,108 +15.7% 3.70 US$159,500
2021-12-13 2021-12-09 B Purchase
1.8
Shanafelt Armen
Non-Executive Director
121,799 +inf%
3.67
US$446,759 		121,799 +inf% 3.67 US$446,759
Explore more

More insider trading research around Spyre Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America